GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chemclin Diagnostics Co Ltd (SHSE:688468) » Definitions » Capex-to-Revenue

Chemclin Diagnostics Co (SHSE:688468) Capex-to-Revenue : 0.55 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chemclin Diagnostics Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Chemclin Diagnostics Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-60.68 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥111.39 Mil.

Hence, Chemclin Diagnostics Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.55.


Chemclin Diagnostics Co Capex-to-Revenue Historical Data

The historical data trend for Chemclin Diagnostics Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemclin Diagnostics Co Capex-to-Revenue Chart

Chemclin Diagnostics Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial 0.12 0.20 0.15 0.27 0.68

Chemclin Diagnostics Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.77 0.74 0.54 0.55

Competitive Comparison of Chemclin Diagnostics Co's Capex-to-Revenue

For the Diagnostics & Research subindustry, Chemclin Diagnostics Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemclin Diagnostics Co's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chemclin Diagnostics Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chemclin Diagnostics Co's Capex-to-Revenue falls into.



Chemclin Diagnostics Co Capex-to-Revenue Calculation

Chemclin Diagnostics Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-301.375) / 445.341
=0.68

Chemclin Diagnostics Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-60.675) / 111.391
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemclin Diagnostics Co  (SHSE:688468) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Chemclin Diagnostics Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chemclin Diagnostics Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemclin Diagnostics Co (SHSE:688468) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Fengxian Middle Road, 6th & 7th Floor Incubator Building, Beike Modern Manufacturing Park, Yongfeng Base, Haidian District, Beijing, CHN, 100094
Chemclin Diagnostics Co Ltd is engaged in the development, production and sales of clinical immunochemiluminescence diagnostic testing reagents and instruments.

Chemclin Diagnostics Co (SHSE:688468) Headlines

No Headlines